Dr. Snider utilizes his expertise in mass spectrometry and chromatography towards assigning the molecular underpinnings of lipid metabolism in cancer. These pathways generate bioactive molecules that have poorly understood turnover and signaling potential. In his research, he has utilized isotopically labeled or odd chain substrates to tease apart the dynamics of de novo lipid metabolism and gained valuable insight into chemotherapeutics actions on these signaling pathways. Currently he is involved in biomarker assay development in prostate and colon cancers, employing untargeted metabolomics techniques to identify critically important metabolites in the progression of these diseases, and then developing quantitative assays for their analysis.